Literature DB >> 3537002

Isotype-specific enzyme immunoassay for influenza antibody with monoclonal antibodies to human immunoglobulins.

M W Harmon, D J Phillips, C B Reimer, A P Kendal.   

Abstract

Mouse monoclonal antibodies specific for human immunoglobulin isotypes were investigated for use in an isotype-specific enzyme immunoassay for detection of antibody to influenza type A hemagglutinin (H1 and H3). The monoclonal antibody reagents were compared with isotype-specific, hyperimmune rabbit antisera from the National Institutes of Health. Endpoint titers for immunoglobulin G (IgG) obtained with the two reagents were within fourfold of each other 84% of the time (79 of 84) and within eightfold of each other 95% of the time (89 of 94). Regression analysis of the data gave a multiple correlation coefficient (r2) of 0.77 and a Spearman rank value of 0.83 (P less than 0.001). For IgA reagents, endpoint titers agreed within fourfold 77% of the time (88 of 114) and within eightfold 92% of the time (105 of 114). The r2 was 0.73, and Spearman rank was 0.83 (P less than 0.001). IgM antibody was detected in only 17 of 114 sera by either monoclonal or polyclonal reagents. Of these sera, 14 (82%) gave titers with the two reagents that were within fourfold of each other. A similar number of fourfold titer rises were detected with each reagent in paired sera showing hemagglutination inhibition titer rises. Monoclonal antibody reagents detected 27 IgA, 29 IgG, and 6 IgM rises, while polyclonal antisera detected 26 IgA, 31 IgG, and 7 IgM rises. These results show that monoclonal antibodies specific for human immunoglobulin isotypes are suitable as reagents for diagnostic assays. The advantages of monoclonal antibodies are their high degree of specificity and the ability to be standardized and produced in unlimited quantities. Moreover, the availability of immunoglobulin subclass- and allotype-specific monoclonal antibodies will enable a more detailed analysis of the antibody response to influenza as well as other infectious agents.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3537002      PMCID: PMC269069          DOI: 10.1128/jcm.24.6.913-916.1986

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  9 in total

1.  Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine.

Authors:  M L Clements; B R Murphy
Journal:  J Clin Microbiol       Date:  1986-01       Impact factor: 5.948

2.  Evaluation of monoclonal antibodies having specificity for human IgG sub-classes: results of an IUIS/WHO collaborative study.

Authors:  R Jefferis; C B Reimer; F Skvaril; G de Lange; N R Ling; J Lowe; M R Walker; D J Phillips; C H Aloisio; T W Wells
Journal:  Immunol Lett       Date:  1985       Impact factor: 3.685

3.  Evaluation of thirty-one mouse monoclonal antibodies to human IgG epitopes.

Authors:  C B Reimer; D J Phillips; C H Aloisio; D D Moore; G G Galland; T W Wells; C M Black; J S McDougal
Journal:  Hybridoma       Date:  1984

4.  Hemagglutinin-specific antibody responses in immunoglobulin G, A, and M isotypes as measured by enzyme-linked immunosorbent assay after primary or secondary infection of humans with influenza A virus.

Authors:  D B Burlington; M L Clements; G Meiklejohn; M Phelan; B R Murphy
Journal:  Infect Immun       Date:  1983-08       Impact factor: 3.441

5.  Hemagglutinin-specific enzyme-linked immunosorbent assay for antibodies to influenza A and B viruses.

Authors:  B R Murphy; M A Phelan; D L Nelson; R Yarchoan; E L Tierney; D W Alling; R M Chanock
Journal:  J Clin Microbiol       Date:  1981-03       Impact factor: 5.948

6.  Monoclonal antibody-based solid-phase immunoenzymometric assays for quantifying human immunoglobulin G and its subclasses in serum.

Authors:  C Papadea; I J Check; C B Reimer
Journal:  Clin Chem       Date:  1985-12       Impact factor: 8.327

7.  Serum antibody responses in naturally occurring influenza A virus infection determined by enzyme-linked immunosorbent assay, hemagglutination inhibition, and complement fixation.

Authors:  H P Madore; R C Reichman; R Dolin
Journal:  J Clin Microbiol       Date:  1983-12       Impact factor: 5.948

8.  Use of the enzyme-linked immunosorbent assay to detect serum antibody responses of volunteers who received attenuated influenza A virus vaccines.

Authors:  B R Murphy; E L Tierney; B A Barbour; R H Yolken; D W Alling; H P Holley; R E Mayner; R M Chanock
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

9.  Subclass distribution and molecular form of immunoglobulin A hemagglutinin antibodies in sera and nasal secretions after experimental secondary infection with influenza A virus in humans.

Authors:  T A Brown; B R Murphy; J Radl; J J Haaijman; J Mestecky
Journal:  J Clin Microbiol       Date:  1985-08       Impact factor: 5.948

  9 in total
  5 in total

1.  Monoclonal antibodies for clinical applications. Patents and literature.

Authors:  J S Dordick
Journal:  Appl Biochem Biotechnol       Date:  1988-12       Impact factor: 2.926

Review 2.  Clinical laboratory applications of monoclonal antibodies.

Authors:  W J Payne; D L Marshall; R K Shockley; W J Martin
Journal:  Clin Microbiol Rev       Date:  1988-07       Impact factor: 26.132

3.  Determination of antibody response to influenza virus surface glycoproteins by kinetic enzyme-linked immunosorbent assay.

Authors:  M H Snyder; S Banks; B R Murphy
Journal:  J Clin Microbiol       Date:  1988-10       Impact factor: 5.948

4.  Rapid detection of influenza A virus infection utilizing an immunomagnetic bead-based microfluidic system.

Authors:  Kang-Yi Lien; Lien-Yu Hung; Tze-Bin Huang; Yi-Che Tsai; Huan-Yao Lei; Gwo-Bin Lee
Journal:  Biosens Bioelectron       Date:  2011-03-16       Impact factor: 10.618

5.  Use of recombinant nucleoproteins in enzyme-linked immunosorbent assays for detection of virus-specific immunoglobulin A (IgA) and IgG antibodies in influenza virus A- or B-infected patients.

Authors:  J T Voeten; J Groen; D van Alphen; E C Claas; R de Groot; A D Osterhaus; G F Rimmelzwaan
Journal:  J Clin Microbiol       Date:  1998-12       Impact factor: 5.948

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.